Article
Predictive value of direct bilirubin and total bile acid in lung adenocarcinoma patients treated with EGFR-TKIs.
BMC pulmonary medicine - 23 Nov 2024
Li Yuting, Wang Bicheng, Fei Shihong, Qin You
Abstract excerpt
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have been the standard treatment for patients with sensitizing EGFR mutation. However, almost all patients eventually acquire resistance to EGFR-TKIs. Therefore, easily available parameters to estimate the outcome of lung adenocarcinoma patients treated with EGFR-TKIs are in urgent need. Lung adenocarcinoma patients harbored EGFR sensitive...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
